TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01635790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
Study: NCT03609216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo radical cystectomy
Study: NCT02161159

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A administered in accordance with physician standard practice.
Study: NCT04136015

Intervention type: DRUG
Intervention: Dasatinib 100 MG
Description: The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group

Intervention type: DRUG
Intervention: Dasatinib 100 MG
Description: The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
Study: NCT00711178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy with methyl aminolevulinate
Description: daylight mediated photodynamic therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy with methyl aminolevulinate
Description: daylight mediated photodynamic therapy
Study: NCT03085849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV on day 8 (flat dose) until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg IV on day 8 (flat dose) x 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle
Study: NCT06251531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapist-Guided Play-Based Intervention (GD-TG-PBI)
Description: The GD-TG-PBI used play to improve performance in targeted functional activities. The program was planned by a physiotherapist with 25 years' experience and an occupational therapist with six years' experience in play. The sessions were based on motor-learning principles supporting cortical plasticity. Individual-specific goals were transformed into play activities that increase occupational participation with regard to the child's abilities, needs, and learning potential. A top-down approach based on direct gamification was adapted without dividing it into components, instead of a component-based, bottom-up approach. Thus, a structured play program was created and an individual-specific intervention was applied in line with the occupational goals and detailed motor evaluations. Positive, active experiences facilitated the adaptation of the learned skills to daily life.
Study: NCT02638454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise
Description: 1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acute Resistance Exercise
Description: 1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise
Description: 1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
Study: NCT03609216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Undergo chemoradiotherapy
Study: NCT00556790

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Care
Description: standard fluid regime, delayed feeding

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fast Track care
Description: restrictive fluid regime, early oral feeding, enforced mobilisation
Study: NCT03521856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shoulder exercise
Description: Exercises performed 3 times a week for 12 weeks
Study: NCT05025319

Intervention type: RADIATION
Intervention: X-ray image
Description: Bedside x-ray at intensive unit.

Intervention type: RADIATION
Intervention: X-ray image
Description: Bedside x-ray at intensive unit.
Study: NCT04215965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphozyl (dialysate and replacement)
Description: Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prismocal B22 (dialysate) + phoxilium (replacement)
Description: solution with phosphate and calcium in CRRT with citratre-based antigoagulation
Study: NCT02319044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 monotherapy
Study: NCT03521856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Study: NCT01103024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03701035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training & UL Motor Training
Description: Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic training & UL Motor Training
Description: 40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
Study: NCT02604901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (BI)
Description: Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.
Study: NCT02319044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab monotherapy
Study: NCT02604901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (BI)
Description: Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pill Box (PB)
Description: Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
Study: NCT02319044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 + Tremelimumab
Description: MEDI4736 + Tremelimumab combination therapy
Study: NCT02317562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I10E
Description: Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
Study: NCT02604901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pill Box (PB)
Description: Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
Study: NCT01528267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous blood
Description: 50mls of autologous blood injected into each of 3 bronchopulmonary segments.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: 50mls of normal saline injected into each of 3 bronchopulmonary segments.
Study: NCT01886599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study: NCT01929304

Intervention type: OTHER
Intervention: Survey

Intervention type: OTHER
Intervention: Survey
Study: NCT00620243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1: FDG PET
Description: The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
Study: NCT04563065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle advise
Description: This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
Study: NCT04041895

Intervention type: OTHER
Intervention: Audio speech recording
Description: Audio recording of speech sample from subject description of Cookie-Theft image.

Intervention type: OTHER
Intervention: Audio speech recording
Description: Audio recording of speech sample from subject description of Cookie-Theft image.
Study: NCT02658812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT
Study: NCT00902603

Intervention type: DRUG
Intervention: Commercial Ventavis® (iloprost)
Description: Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
Study: NCT04307238

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PLR
Description: PLR measurements will be performed within the first 2 postoperative hours.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PLR
Description: PLR measurements will be performed within the first 2 postoperative hours.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Alertness testing
Description: Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Alertness testing
Description: Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Propofol anesthesia
Description: Maintenance of anesthesia will be performed using propofol.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sevoflurane anesthesia
Description: Maintenance of anesthesia will be performed using sevoflurane.
Study: NCT01814163

Intervention type: DRUG
Intervention: paclitaxel, carboplatin and bevacizumab
Description: Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
Study: NCT03299803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men's Healing Pathways
Description: Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
Study: NCT01660217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A written Eczema Action Plan (EAP)
Description: A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A written Eczema Action Plan (EAP)
Description: A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
Study: NCT03682315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic phycogenic biomaterial
Description: Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenograft bovine hydroxyapatite
Description: Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
Study: NCT01625520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 alone or in combination with RAD001.
Description: SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
Study: NCT02409238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
Study: NCT00567177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis, Refresh Plus
Description: Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Restasis, Refresh Plus
Description: Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
Study: NCT01520623

Intervention type: OTHER
Group type: OTHER
Intervention: Serum concentration /Serum inflammatory
Description: Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
Study: NCT03621800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol popsicle
Description: The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
Study: NCT02627209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spectrophotometric assay
Description: measurement of enzyme activity in the serum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spectrophotometric assay
Description: measurement of enzyme activity in the serum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radial immunodiffusion
Description: measurement of the precipitated ring diameters showing enzyme activity in the serum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radial immunodiffusion
Description: measurement of the precipitated ring diameters showing enzyme activity in the serum
Study: NCT03755609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 0.1 mg/kg intravenously

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: fentanyl
Description: 1ug/kg intravenously
Study: NCT02729376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galeterone
Study: NCT02032888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT02409238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.~This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard LIfestyle Recommendation
Description: The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
Study: NCT02032888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study: NCT03963206

Intervention type: DRUG
Group type: OTHER
Intervention: Cabozantinib group
Description: The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
Study: NCT03923179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib, 400mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide, 50mg，qd,d1-21,Q4W
Study: NCT00803764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tablets, 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tablets, 500 mg
Study: NCT03902028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reinforced multidisciplinary follow-up
Description: Reinforced multidisciplinary follow-up
Study: NCT00487500

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Description: Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Description: Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
Study: NCT02559700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain training programme
Description: An online package of brain training programmes
Study: NCT03168958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone will be provided at induction of anesthesia

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline will be administered at induction of anesthesia
Study: NCT04330729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Se arm description